ATE206708T1 - Benzimidazolonderivate mit zentraler dopaminerger aktivität - Google Patents

Benzimidazolonderivate mit zentraler dopaminerger aktivität

Info

Publication number
ATE206708T1
ATE206708T1 AT95914492T AT95914492T ATE206708T1 AT E206708 T1 ATE206708 T1 AT E206708T1 AT 95914492 T AT95914492 T AT 95914492T AT 95914492 T AT95914492 T AT 95914492T AT E206708 T1 ATE206708 T1 AT E206708T1
Authority
AT
Austria
Prior art keywords
dopaminergic activity
central dopaminergic
benzimidazolone derivatives
derivatives
benzimidazolone
Prior art date
Application number
AT95914492T
Other languages
English (en)
Inventor
Anton F Fliri
Brian T O'neill
William S Faraci
Mark A Sanner
Stevin H Zorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE206708T1 publication Critical patent/ATE206708T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT95914492T 1994-06-14 1995-04-24 Benzimidazolonderivate mit zentraler dopaminerger aktivität ATE206708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25970794A 1994-06-14 1994-06-14
PCT/IB1995/000285 WO1995034555A1 (en) 1994-06-14 1995-04-24 Benzimidazolone derivatives with central dopaminergic activity

Publications (1)

Publication Number Publication Date
ATE206708T1 true ATE206708T1 (de) 2001-10-15

Family

ID=22986031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914492T ATE206708T1 (de) 1994-06-14 1995-04-24 Benzimidazolonderivate mit zentraler dopaminerger aktivität

Country Status (11)

Country Link
EP (1) EP0765320B1 (de)
JP (1) JP2860604B2 (de)
AT (1) ATE206708T1 (de)
CA (1) CA2192975C (de)
DE (1) DE69523155T2 (de)
DK (1) DK0765320T3 (de)
ES (1) ES2163506T3 (de)
FI (1) FI113767B (de)
MX (1) MX9606450A (de)
PT (1) PT765320E (de)
WO (1) WO1995034555A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A3 (de) * 1998-04-29 2003-04-02 Pfizer Products Inc. Bizyklisch substituierte Piperazin-, Piperidin- und Tetrahydropyridin Derivate, deren Herstellung und deren Verwendung als Mittel mit zentraler dopaminerger (Dopamin D4 Rezeptor) Aktivität
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EP1177792A3 (de) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamin-d4-ligande zur behandlung von gaudi-suchenden krankheiten
EP1322621B1 (de) * 2000-09-19 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co.KG Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
EP1945214A1 (de) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolon-derivate zur behandlung von prämenstruellen und anderen sexuellen störungen der frau
EP2133338A1 (de) 2006-05-09 2009-12-16 AstraZeneca AB Salzformen von (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-Penten-2-Amin
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
ES2336719T3 (es) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas.
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
KR20130081221A (ko) 2010-05-20 2013-07-16 아스트라제네카 아베 아릴 치환된 올레핀계 아민의 신규 제조 방법
JP2018112616A (ja) 2017-01-10 2018-07-19 富士フイルム株式会社 積層体、積層体の製造方法、および車両用ルームミラー
CN115836054A (zh) * 2020-05-06 2023-03-21 默沙东有限责任公司 Il4i1抑制剂和使用方法
EP4308119A1 (de) * 2021-03-19 2024-01-24 Centre National de la Recherche Scientifique <sup2/>? <sub2/>?7?anwendungen von vorbelasteten serotonin 5-ht-rezeptor liganden zur behandlung von schmerzen, multipler sklerose und kontrolle der thermoregulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
EP0765320A1 (de) 1997-04-02
FI965021A0 (fi) 1996-12-13
FI113767B (fi) 2004-06-15
MX9606450A (es) 1997-03-29
CA2192975C (en) 1999-09-21
CA2192975A1 (en) 1995-12-21
DE69523155T2 (de) 2002-02-07
JPH09506637A (ja) 1997-06-30
PT765320E (pt) 2002-02-28
EP0765320B1 (de) 2001-10-10
WO1995034555A1 (en) 1995-12-21
ES2163506T3 (es) 2002-02-01
DE69523155D1 (de) 2001-11-15
FI965021A (fi) 1996-12-13
DK0765320T3 (da) 2001-11-26
JP2860604B2 (ja) 1999-02-24

Similar Documents

Publication Publication Date Title
DE69523155T2 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
SE9604786D0 (sv) New compounds
DE59709414D1 (de) Oxyiminopregnancarbolactone
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
FI970469A (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması
NO970498L (no) Benzimidazolderivater med dopaminergisk aktivitet
MX9704299A (es) Derivados de bencimidazol.
ECSP951500A (es) Derivados de bencimidazol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee